JUN and neoplasm: In cisplatin-resistant tumour cells, ANXA2 promotes c-Jun N-terminal kinase (JNK) phosphorylation, and p-JNK induces c-Jun/p53 complex formation, thereby reducing p53 expression and inhibiting apoptosis [50].